Compare Stocks: JANX, DNLI, VKTX, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.20 -2.9%	$24.49	$12.58 ▼ $27.30	$3.98B	1.01	1.36 million shs	1.32 million shs
JANX Janux Therapeutics	$18.60 +7.0%	$15.76	$12.12 ▼ $35.34	$1.06B	2.5	686,174 shs	1.45 million shs
LEGN Legend Biotech	$20.94 -4.0%	$24.29	$16.24 ▼ $37.50	$4.05B	0.37	2.97 million shs	1.93 million shs
VKTX Viking Therapeutics	$33.23 -1.9%	$35.36	$22.96 ▼ $43.15	$3.95B	0.69	1.90 million shs	1.75 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-2.89%	-0.62%	+4.72%	+24.87%	+56.23%
JANX Janux Therapeutics	+6.96%	+14.39%	+21.33%	+29.17%	-23.46%
LEGN Legend Biotech	-4.03%	+1.40%	-5.76%	-29.09%	-41.11%
VKTX Viking Therapeutics	-1.95%	-1.19%	-4.48%	+7.89%	+27.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.20 -2.9%	$24.49	$12.58 ▼ $27.30	$3.98B	1.01	1.36 million shs	1.32 million shs
JANX Janux Therapeutics	$18.60 +7.0%	$15.76	$12.12 ▼ $35.34	$1.06B	2.5	686,174 shs	1.45 million shs
LEGN Legend Biotech	$20.94 -4.0%	$24.29	$16.24 ▼ $37.50	$4.05B	0.37	2.97 million shs	1.93 million shs
VKTX Viking Therapeutics	$33.23 -1.9%	$35.36	$22.96 ▼ $43.15	$3.95B	0.69	1.90 million shs	1.75 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-2.89%	-0.62%	+4.72%	+24.87%	+56.23%
JANX Janux Therapeutics	+6.96%	+14.39%	+21.33%	+29.17%	-23.46%
LEGN Legend Biotech	-4.03%	+1.40%	-5.76%	-29.09%	-41.11%
VKTX Viking Therapeutics	-1.95%	-1.19%	-4.48%	+7.89%	+27.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.92	48.42% Upside
JANX Janux Therapeutics	2.57	Moderate Buy	$36.46	96.03% Upside
LEGN Legend Biotech	2.47	Hold	$52.29	149.69% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	190.78% Upside

Current Analyst Ratings Breakdown

Latest JANX, DNLI, VKTX, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $49.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/12/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$80.00 ➝ $78.00
8/12/2026	LEGN Legend Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$29.00 ➝ $24.00
8/12/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$59.00 ➝ $58.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/11/2026	VKTX Viking Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$75.00 ➝ $65.00
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	11.70	N/A	N/A	$6.91 per share	3.50
JANX Janux Therapeutics	$24M	47.38	N/A	N/A	$15.91 per share	1.17
LEGN Legend Biotech	$1.03B	3.78	N/A	N/A	$5.43 per share	3.86
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	17.90	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest JANX, DNLI, VKTX, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	0.01	8.37	8.32
JANX Janux Therapeutics	N/A	16.35	16.35
LEGN Legend Biotech	N/A	3.04	2.94
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
JANX Janux Therapeutics	75.39%
LEGN Legend Biotech	70.89%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	9.70%
JANX Janux Therapeutics	7.90%
LEGN Legend Biotech	0.02%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	159.85 million	144.34 million	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

JANX, DNLI, VKTX, and LEGN Headlines

Recent News About These Companies

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX

August 22 at 5:11 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research

August 20, 2026 | marketbeat.com

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?

August 19, 2026 | finance.yahoo.com

Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX

August 19, 2026 | marketbeat.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 19, 2026 | finance.yahoo.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 17, 2026 | zacks.com

2 GLP-1 Stocks That Could Double Your Money by 2031

August 16, 2026 | fool.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

August 16, 2026 | theglobeandmail.com

Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX

August 15, 2026 | marketbeat.com

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

August 14, 2026 | finance.yahoo.com

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

August 12, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price

August 11, 2026 | marketbeat.com

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

August 8, 2026 | fool.com

Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX

August 8, 2026 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

August 8, 2026 | marketbeat.com

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

August 6, 2026 | fool.com

First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX

August 6, 2026 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why

August 4, 2026 | finance.yahoo.com

Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?

August 4, 2026 | finance.yahoo.com

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

August 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, VKTX, and LEGN Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$24.20 -0.72 (-2.89%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$24.35 +0.15 (+0.62%)

As of 06:11 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Janux Therapeutics NASDAQ:JANX

$18.60 +1.21 (+6.96%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$18.67 +0.07 (+0.37%)

As of 05:59 AM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$20.94 -0.88 (-4.03%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$21.06 +0.13 (+0.60%)

As of 06:18 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Viking Therapeutics NASDAQ:VKTX

$33.23 -0.66 (-1.95%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$33.72 +0.49 (+1.46%)

As of 06:25 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, DNLI, VKTX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, DNLI, VKTX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, DNLI, VKTX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, VKTX, and LEGN Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Janux Therapeutics NASDAQ:JANX

Legend Biotech NASDAQ:LEGN

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, DNLI, VKTX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, DNLI, VKTX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, DNLI, VKTX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, VKTX, and LEGN Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Janux Therapeutics NASDAQ:JANX

Legend Biotech NASDAQ:LEGN

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools